The latest news from academia, regulators
research labs and other things of interest
Posted: Apr 19th, 2012
Duke University Uses Nanoparticle Tracking Analysis to Characterize Nanoconstructs for Biomedical Applications
(Nanowerk News) NanoSight, leading manufacturers of unique nanoparticle characterization technology, reports on the work of Professor Tuan Vo-Dinh's group at Duke University where they apply Nanoparticle Tracking Analysis (NTA) to characterize metal nanoparticle construct materials for use in biosensing, imaging and cancer therapy.
The Vo-Dinh Lab is a part of the Departments of Biomedical Engineering and Chemistry of Duke University. The Vo-Dinh Lab is also a part of the Fitzpatrick Institute for Photonics, of which Professor Vo-Dinh is the director.
Professor Tuan Vo-Dinh discusses results from his NanoSight NS500 with Dr Hsiangkuo Yuan from his research group.
The main research goal of the group is to develop advanced techniques and methods to protect the environment (environmental sensors) and improve human health (medical diagnostics and therapy). As a part of these research goals, Dr Hsiangkuo Yuan and other members of Professor Vo-Dinh's group design and fabricate metal nanoparticle constructs such as gold nanostar platforms. These are characterized with UV-VIS, TEM, Raman microscope, fluorometers and other techniques. However, to design nanoconstructs for in vivo applications, the particle size needs to be in the range from 10 to 100 nm for lower clearance from the kidney and reticuloendothelial system (RES). It is important that the construct is in the right size range and is physiologically stable (non-aggregated) for biomedical applications in, for example, optical imaging or nanodrug delivery where it is also critical that the nanoparticle dose administered can be determined. To compare plasmonic properties, i.e. the enhanced electromagnetic properties of nanoparticles, they need to determine the effect of different sizes and to understand in detail the profile of the particle size distribution of similar concentrations which can be obtained using NanoSight's NTA system.
Prior to NTA, the group mostly used TEM to look at particle shape and measure particle size. The surface coating or the aggregation state cannot be easily investigated using just TEM. NanoSight provides a significant complementary role on providing hydrodynamic size distribution and zeta potential. Moreover, because NanoSight gives the concentration information, it allows them to normalize their comparison by individual particle counting which was quite difficult to obtain previously.
Commenting on the benefits of using the NanoSight alongside TEM (for size) and atomic absorption spectroscopy (for mass), Professor Vo-Dinh said the ability to make characterization particle by particle provides complementary information to the ensemble characterization (e.g. DLS). The group have published nanoconstruct data, specifically gold nanostars, in the journal, Nanotechnology, with another paper currently in press, Nanomedicine. They report the determination of particle hydrodynamic size distribution, zeta potential and concentration using NTA.
To find out about the company and to learn more about particle characterization using NanoSight's unique nanoparticle tracking analysis solutions, visit www.nanosight.com and register to receive the next issue of NanoTrail, the company's electronic newsletter.
NanoSight delivers the world's most versatile and proven multi-parameter nanoparticle analysis in a single instrument.
NanoSight's "Nanoparticle Tracking Analysis" (NTA) detects and visualizes populations of nanoparticles in liquids down to 10 nm, dependent on material, and measures the size of each particle from direct observations of diffusion. Additionally, NanoSight measures concentration and a fluorescence mode differentiates suitably-labelled particles within complex background suspensions. Zeta potential measurements assess the surface charge on particles. NTA's particle-by-particle methodology goes beyond traditional light scattering and other ensemble techniques in providing high-resolution particle size distributions and validates data with information-rich video files of the particles moving under Brownian motion.
NanoSight's simultaneous multiparameter characterization matches the demands of complex biological systems, hence its wide application in development of drug delivery systems, of viral vaccines, and in nanotoxicology. This real-time data gives insight into the kinetics of protein aggregation and other time-dependent phenomena in a qualitative and quantitative manner. NanoSight has a growing role in biodiagnostics, being proven in detection and speciation of nanovesicles (exosomes) and microvesicles.
NanoSight has installed more than 450 systems worldwide with users including BASF, GlaxoSmithKline, Merck, Novartis, Pfizer, Proctor and Gamble, Roche and Unilever together with the most eminent universities and research institutes. NanoSight's technology is validated by 400+ third party papers citing NanoSight results, consolidating NanoSight's leadership position in nanoparticle characterization. For more information, visit www.nanosight.com
Source: NanoSight (press release)
Translate this article:
Check out these other trending stories on Nanowerk: